New gene therapy treatment for patients with relapsed or refractory large B-cell lymphoma
EMA has recommended granting a marketing authorisation in the EU for Breyanzi (lisocabtagene maraleucel), a gene therapy for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), whose cancer has come back or who have not responded to treatment after two or more lines of systemic therapy.
Read EMA’s full press release from 28 January 2022.
OpenEdition vous propose de citer ce billet de la manière suivante :
egennet (16 mai 2022). New gene therapy treatment for patients with relapsed or refractory large B-cell lymphoma. ELSIBI. Consulté le 16 janvier 2025 à l’adresse https://doi.org/10.58079/o5y3
